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BACKGROUND: The mechanisms leading to hepatic
injury in chronic hepatitis C virus (HCV) infection
are only incompletely understood. Recent data pro-
pose a correlation of the intrahepatic expression of
the CC chemokine RANTES and the degree of peri-
portal and portal inflammatory liver damage.
Aim: Here, we have studied the intrahepatic mRNA
levels of CC chemokines RANTES together with that
of other members of this chemokine family (MIP-1b,
MCP-1, and MCP-2) in chronic hepatitis C as com-
pared with healthy controls.
Methods: Liver samples from 22 HCV-infected pa-
tients, nine individuals with primary biliary cirrhosis
and from 12 normal controls were included into this
study. Intrahepatic mRNA levels of CC chemokines
RANTES, MIP-1b, MCP-1, and MCP-2 were analyzed by
a semi-quantitative reverse transcription/real-time
polymerase chain reaction assay.
Results: In chronic HCV infection, intrahepatic
RANTES mRNA levels were significantly higher than
in non-infected controls (7.2-fold, p B /0.001) or in the
disease control group (2.8-fold, p B /0.001) and higher
levels of RANTES mRNA levels were observed in livers
with an advanced stage of liver cell injury (histologic
activity index ] /6), although this difference was not
statistically significant (p /0.08). In contrast, mRNA
levels of MIP-1b (p /0.021) and MCP-1 (p /0.021)
were significantly lower in HCV liver samples while
MCP-2 expression was similar in all groups analyzed.
Conclusion: The data support the concept of chemo-
kines as mediators of liver cell injury in chronic
hepatitis C.
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Hepatitis C virus (HCV) leads to persistent infection
in the majority of patients, with possible conse-
quences of chronic liver disease progressing to liver
fibrosis, cirrhosis and/or hepatocellular carcinoma.
1
The mechanisms of tissue damage in chronic HCV
infection are not completely understood. There is,
however, increasing evidence that tissue damage
might be the consequence of an ongoing intrahepatic
antiviral immune response. T lymphocytes are re-
garded as the main cell population infiltrating the
areas of liver damage leading to periportal necro-
sis.
2,3 Migration of T lymphocytes critically depends
on the local production of chemotactic cytokines,
called chemokines, within inflamed tissues.
4 The
subgroup of CC chemokines comprises RANTES
(regulated on activation, normally T cell-expressed
and secreted), MIP-1b, MCP-1 and, MCP2, which
show chemotactic activity preferentially for T cells.
5
Importantly, intrahepatic production of RANTES has
been suggested to be involved in the progression of
chronic hepatitis C to advanced forms of liver
disease.
2,3,6 Here, we have investigated the intrahe-
patic mRNA levels of the CC chemokines MIP-1b,
MCP1, MCP2 and RANTES in a total of 45 liver
specimens from three groups: group 1, chronic HCV
infection (n  /22; patient characteristics presented in
Table 1); group 2, disease control (n  /9: patients
with primary biliary cirrhosis according to interna-
tionally accepted criteria including antimitochondrial
antibodies and liver histology REF); group 3, normal
controls (n  /12; donor liver at the time of hepatect-
omy/unaffected areas from liver resection for sec-
ondary hepatic malignancy).
Determination of intrahepatic chemokine mRNA
levels was carried out with a previously described
semi-quantitative reverse transcription/real-time
polymerase chain reaction assay.
7 The study was
approved by the local ethics committee and con-
formed with the ethical guidelines of the 1975
Declaration of Helsinki. Informed consent was ob-
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357tained from all patients. Briefly, total RNA was
isolated from snap-frozen liver specimens (Trizol
reagent; Life Technologies, Eggenstein, Germany)
and 1 mg was reverse transcribed for 45 min at 428C
and for 30 min at 558C using 0.5 mg of random
hexamer primers (Promega, Heidelberg, Germany)
and 200 units of Superscript Plus RT (Life Technol-
ogies, Eggenstein, Germany). For semiquantitative
analysis of chemokine mRNA levels, samples were
prepared in a final volume of 10 ml, containing 1 mlo f
either external standards or cDNA equivalent to 20 ng
of total RNA, 1 ml of LightCycler FastStart DNA Master
SYBR Green I Mix (Roche Molecular Biochemicals,
Mannheim, Germany), 3.5 mM MgCl and 0.5 mMo f
each of the following primers (Tib MolBiol, Berlin,
Germany): RANTES, 5?-acc aca ccc tgc tgc ttt gc-3?
(forward) and 5?-ccg aac cca ttt ctt ctc tgg-3? (reverse);
MIP-1b,5 ?-acc ctc cca ccg cct gct gc-3?(forward) and
5?-gtt gca ggt cat aca cgt act cc-3? (reverse); MCP-1, 5?-
gat ctc agt gca gag gct cg-3? (forward) and 5?-tgc ttg
tcc agg tgg tcc at-3? (reverse); MCP-2, 5?-atg ctg aag
ctc aca ccc ttg ccc-3? (forward) and 5?-cag atg ctt cat
gga atc cct gac c-3? (reverse). The thermal profile
settings were as follows: initial denaturation (7 min/
958C), followed by 35 amplification cycles: 3 sec/
658C( b-actin, 608C); 15 sec/728C( b-actin, 30 sec);
Table 1. HCV patient characteristics




















Median histological activity index (range)
Inflammation 4 points (1 /9)
Fibrosis 1 point (0 /5)
Total score 5 points (1 /12)
* Inno-Lipa HCV II line probe assay (Innogenetics, Zwijndrecht,
Belgium).
$ Amplicor HCV Monitor (Roche Diagnostic Systems, Branchburgh,
USA).
FIG. 1. Semiquantitative determination of intrahepatic steady-state mRNA levels in HCV infection. CC chemokine mRNA levels
were detemined in liver specimens from patients with chronic hepatitis C (n  /22), PBC (n  /9) and normal controls (n  /12).
Results of semiquantitative determination of intrahepatic steady-state mRNA levels of RANTES (upper left), MIP-1b (upper
right), MCP1 (lower left), and MCP2 (lower right) in liver specimens from patients with chronic hepatitis C (n  /22), primary
biliary cirrhosis (n  /9) and normal controls (n  /12). As shown we found signiﬁcantly increased levels of RANTES mRNA but
decreased levels of MIP-1b and MCP1 in livers from HCV-infected patients as compared with the control groups. Data
presented as boxplots showing median, quartiles and extreme values; p values presented as calculated with Mann /Whitney
U-test.
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358 Mediators of Inflammation Vol 13  20040 sec/958C followed by melting curve analysis
(increasing temperature from 60 /958C). Acquisition
temperature for the fluorescence signal was adjusted
to 858C( b-actin, RANTES, MIP1b)o r8 4 8C (MCP-1,
MCP2), respectively. Results were standardized with
respect to mRNA levels of the housekeeping gene
b-actin measured with primers for 5?-cgg gaa atc gtg
cgt gac at-3? (sense) and 5?-gaa ctt tgg ggg atg ctc gc-
3? (antisense). A multi-specific competitor fragment
was used as external standard.
7,8
In confirmation of preliminary data,
7 we observed
markedly lower intrahepatic MIP-1b and MCP-1
mRNA levels in HCV-infected patients than in con-
trols (Fig. 1) while MCP-2 mRNA levels were similar
in the three groups studied (Fig. 1). In contrast, we
found significantly higher intrahepatic RANTES
mRNA levels in specimens from chronic hepatitis C
than in normal controls (7.2-fold, p B /0.001) or in the
disease control group (2.8-fold, p B /0.001; Fig. 1).
Investigating a possible correlation with clinical,
laboratory or virological data we found that liver
samples with a more severe degree of intrahepatic
inflammation (histologic activity index ] /6) showed
a trend towards higher RANTES mRNA levels
(p  /0.08), while no significant correlation was found
between intrahepatic chemokine mRNA levels and
patient characteristics (age, risk factor) or character-
istics of viral infection (viral load or genotype; data
not shown).
MCP-1 can be induced in many cell types including
hepatocytes, Kupffer cells and stellate cells.
9 The
finding of lower intrahepatic MCP-1 mRNA levels are
in contrast to a recent report on a trend towards
increased intrahepatic MCP-1 mRNA levels in chronic
HCV infection.
3 This discrepancy could be due to
differences in the composition of the patient popula-
tion and/or methods of chemokine mRNA determi-
nation. Our data, however, fit well with reports on
downregulation of MCP-1 expression by viral pro-
teins. Thus, MCP-1 expression was downregulated in
hepatitis B virus X protein transgenic cells
10 and the
activity of the MCP-1 gene promoter was inhibited by
HCV core protein.
11 It is therefore tempting to
speculate that lower intrahepatic MCP-1 mRNA levels
are the consequence of an interaction of HCV with
the gene expression of host cells.
In line with previous reports
3 we found higher
intrahepatic RANTES mRNA levels in chronic hepati-
tis C. Moreover, it has been described that the
enhanced expression of RANTES mRNA correlates
to CD8 gene expression and to the extent of liver
damage, suggesting that a release of proinflammatory
cytokines by activated T cells contributes to immune-
mediated liver damage in hepatitis C.
2,3,12 Again, in
line with these observations, we observed a trend
towards higher RANTES mRNA levels in liver samples
with a more severe degree of intrahepatic inflamma-
tion. In addition, we could recently demonstrate that
exposure of CD8
  T cells to HCV E2 results in an
enhanced release of RANTES and an increase, albeit
smaller, in RANTES mRNA.
13 Alternatively, increased
RANTES mRNA levels could be due to a direct
interaction of HCV with the gene expression of the
host cell that has been described for hepatic cell
lines.
11
In summary, the data presented suggest distinct
alterations of intrahepatic CC chemokine mRNA
levels. While there is some evidence to suggest that
this may be the result of an interaction of viral
proteins with host cells, the significance of these
alterations in the intrahepatic CC chemokine pattern
for the pathogenesis of chronic hepatitis C virus
infection remains to be elucidated.
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